We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




MicroRNA Mimic Shown to Reverse Effects of Pulmonary Fibrosis

By LabMedica International staff writers
Posted on 29 Sep 2014
Print article
A potential new treatment that reverses the effects of pulmonary fibrosis, a respiratory disease in which scars develop in the lungs and greatly suppress breathing, is being assessed by scientists. The therapy uses a microRNA mimic, miR-29, which is delivered to lung tissue intravenously. In lab mice, miR-29 not only blocked pulmonary fibrosis, it reversed fibrosis after several days.

The findings were published September 19, 2014, in the journal EMBO Molecular Medicine. “The mimic, when injected into the blood, goes to the lung and it has a sustained effect. We are very impressed that it can reverse fibrosis, not only prevent it,” said Naftali Kaminski, MD, a professor at the Yale School of Medicine (New Haven, CT, USA), and section chief of pulmonary, critical care, and sleep medicine, and corresponding author of the study.

The research is a collaboration between Yale and miRagen Therapeutics Boulder, CO, USA), a pharmaceutical company. The company had developed miR-29 earlier as a possible therapy for cardiac disease. Dr. Kaminski, whose group innovated research in microRNA in lung fibrosis, visualized the potential for use of miR-29 in pulmonary fibrosis, as did Dr. Eva van Rooij, the scientist who discovered the role for miR-29 in cardiac fibrosis, and is a senior coauthor on the study. “I’m particularly excited about working with this microRNA,” said Dr. van Rooij. “All evidence points to it being a master regulator of fibrosis.”

The next phase of the study, according to Dr. Kaminski, will be to begin evaluating miR-29 as a therapeutic for human idiopathic pulmonary fibrosis (IPF). Once considered a rare disease, IPF now affects more than 200,000 people in the United States, where approximately 30,000 people die from IPF every year. The median survival from diagnosis is three to five years, and in spite of recent potential developments, there is no intervention that reverses the disease.

Related Links:
Yale School of Medicine
miRagen Therapeutics


New
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Automated Blood Typing System
IH-500 NEXT
New
Thyroxine ELISA
T4 ELISA
New
Alpha-1-Antitrypsin ELISA
IDK alpha-1-Antitrypsin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.